Full Press Release Details
Acquisition to expand urology offerings for people living with overactive bladder
MARLBOROUGH, Mass. , Jan. 12, 2026 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX ) today announced it has entered into a definitive agreement to acquire Valencia Technologies Corporation, a privately held medical technology company focused on the development and commercialization of innovative solutions to treat bladder dysfunction. The company's eCoin® System is an implantable tibial nerve stimulation (ITNS) device for the treatment of urge urinary incontinence (UUI), a common symptom of overactive bladder (OAB).
In the United States, nearly 30 million adults ages 40 and older have bothersome symptoms of OAB. 1 The condition can have a significant impact on quality of life, mental health, sleep, productivity and social activities. 2 One study found that the overall treatment rate for OAB, beyond behavioral and lifestyle adjustments, was approximately 19%. 3
The eCoin system, approved by the U.S. Food and Drug Administration in 2022, is a coin-sized device that is placed under the skin, near the ankle, during a minimally invasive procedure. The device is intended for patients who have undergone a successful trial of percutaneous tibial nerve stimulation (PTNS) or for patients who are intolerant to or have an inadequate response to more conservative UUI treatments. Once implanted, the device intermittently and automatically stimulates the tibial nerve to help regulate how the brain communicates with the bladder. In the eCoin pivotal clinical trial, 68% of patients responded with at least a 50% reduction in UUI episodes. 4
"The addition of the eCoin system to the Boston Scientific portfolio will enable us to expand into implantable tibial nerve stimulation (ITNS), a high-growth adjacency for our Urology business," said Meghan Scanlon, senior vice president and president, Urology, Boston Scientific. "ITNS technology complements our existing pelvic health product line, and we look forward to offering a more comprehensive set of treatment options to patients across the care continuum."
Boston Scientific expects to complete the acquisition in the first half of 2026, subject to customary closing conditions. The transaction is expected to have an immaterial impact on adjusted earnings per share in 2026 and is expected to be more dilutive on a GAAP basis due to acquisition-related net charges and amortization expense. Specific terms of the transaction have not been disclosed.
Cautionary Statement Regarding Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "may," "intend" and similar words. These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance. These forward-looking statements include, among other things, statements regarding our business plans, the financial and business impact of the transaction and the anticipated benefits of the transaction, the closing of the transaction and the timing thereof, and product performance and impact. If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements. These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release. As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.
CONTACTS: Nate Gilbraith Media Relations +1 (701) 212-9589 [email protected]
Lauren Tengler Investor Relations +1 (508) 683-4479 [email protected]
1 Coyne, et al. "National community prevalence of overactive bladder in the United States stratified by sex and age." Urology. Volume 77, Issue 5, P1081-1087, MAY 2011. DOI: https://doi.org/10.1016/j.urology.2010.08.039
2 Reynolds, et al. "The Burden of Overactive Bladder on US Public Health." Curr Bladder Dysfunct Rep, Mar 2016.
3 Mohamud H, et al. Trends in Overactive Bladder Therapy: Associations Between Clinical Care Pathways, Practice Guidelines, and Therapy Utilization Patterns. Neurourol Urodyn. 2025 Feb;44(2):319-329. doi: 10.1002/nau.25627.
4 Rogers A, et al. Pivotal study of leadless tibial nerve stimulation with eCoin ® for urgency urinary incontinence: an open-label, single arm trial. Journal of Urology. August 2021. DOI: https://doi.org/10.1097/JU.0000000000001733
SOURCE Boston Scientific Corporation